Silencing Mutant ATXN3 Expression Resolves Molecular Phenotypes in SCA3 Transgenic Mice

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2013 Jul 4

PMID 23820820

Citations 65

Authors

Edgardo Rodriguez-Lebron

Maria do Carmo Costa

Maria doCarmo Costa

Katiuska Luna-Cancalon

Therese M Peron

Svetlana Fischer

Ryan L Boudreau

Beverly L Davidson

Henry L Paulson

Affiliations

Soon will be listed here.

Abstract

Spinocerebellar ataxia type 3 (SCA3) is a neurodegenerative disease caused by a polyglutamine expansion in the deubiquitinating enzyme, Ataxin-3. Currently, there are no effective treatments for this fatal disorder but studies support the hypothesis that reducing mutant Ataxin-3 protein levels might reverse or halt the progression of disease in SCA3. Here, we sought to modulate ATXN3 expression in vivo using RNA interference. We developed artificial microRNA mimics targeting the 3'-untranslated region (3'UTR) of human ATXN3 and then used recombinant adeno-associated virus to deliver them to the cerebellum of transgenic mice expressing the full human disease gene (SCA3/MJD84.2 mice). Anti-ATXN3 microRNA mimics effectively suppressed human ATXN3 expression in SCA3/MJD84.2 mice. Short-term treatment cleared the abnormal nuclear accumulation of mutant Ataxin-3 throughout the transduced SCA3/MJD84.2 cerebellum. Analysis also revealed changes in the steady-state levels of specific microRNAs in the cerebellum of SCA3/MJD84.2 mice, a previously uncharacterized molecular phenotype of SCA3 that appears to be dependent on mutant Ataxin-3 expression. Our findings support the preclinical development of molecular therapies aimed at halting the expression of ATXN3 as a viable approach to SCA3 and point to microRNA deregulation as a potential surrogate marker of SCA3 pathogenesis.

Citing Articles

Quantification of Solid Embryonic Cerebellar Graft Volume in a Degenerative Ataxia Model.

Purkartova Z, Krakorova K, Babuska V, Tuma J, Houdek Z, Roy Choudhury N Cerebellum. 2024; 23(5):1811-1823.

PMID: 38430389 DOI: 10.1007/s12311-024-01676-z.

Hereditary Ataxias: From Bench to Clinic, Where Do We Stand?.

Pilotto F, Del Bondio A, Puccio H Cells. 2024; 13(4.

PMID: 38391932 PMC: 10886822. DOI: 10.3390/cells13040319.

Blood levels of neurofilament light are associated with disease progression in a mouse model of spinocerebellar ataxia type 3.

Mengel D, Wellik I, Schuster K, Jarrah S, Wacker M, Ashraf N Dis Model Mech. 2023; 16(9).

PMID: 37664882 PMC: 10499033. DOI: 10.1242/dmm.050144.

Therapeutic effects of engineered exosome-based miR-25 and miR-181a treatment in spinocerebellar ataxia type 3 mice by silencing ATXN3.

Tang Z, Hu S, Wu Z, He M Mol Med. 2023; 29(1):96.

PMID: 37438701 PMC: 10337053. DOI: 10.1186/s10020-023-00695-6.

Tissue-Specific Vulnerability to Apoptosis in Machado-Joseph Disease.

Ferreira A, Raposo M, Shaw E, Ashraf N, Medeiros F, Brilhante M Cells. 2023; 12(10).

PMID: 37408238 PMC: 10216795. DOI: 10.3390/cells12101404.

References

Cemal C, Carroll C, Lawrence L, Lowrie M, Ruddle P, Al-Mahdawi S . YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet. 2002; 11(9):1075-94. DOI: 10.1093/hmg/11.9.1075. View

Grimson A, Farh K, Johnston W, Garrett-Engele P, Lim L, Bartel D . MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007; 27(1):91-105. PMC: 3800283. DOI: 10.1016/j.molcel.2007.06.017. View

McBride J, Boudreau R, Harper S, Staber P, Monteys A, Martins I . Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A. 2008; 105(15):5868-73. PMC: 2311380. DOI: 10.1073/pnas.0801775105. View

Walsh R, Storey E, Stefani D, Kelly L, Turnbull V . The roles of proteolysis and nuclear localisation in the toxicity of the polyglutamine diseases. A review. Neurotox Res. 2005; 7(1-2):43-57. DOI: 10.1007/BF03033775. View

Li L, Yu Z, Teng X, Bonini N . RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature. 2008; 453(7198):1107-11. PMC: 2574630. DOI: 10.1038/nature06909. View

Zu T, Duvick L, Kaytor M, Berlinger M, Zoghbi H, Clark H . Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J Neurosci. 2004; 24(40):8853-61. PMC: 6729947. DOI: 10.1523/JNEUROSCI.2978-04.2004. View

Xia H, Mao Q, Eliason S, Harper S, Martins I, Orr H . RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med. 2004; 10(8):816-20. DOI: 10.1038/nm1076. View

Rodrigues A, Coppola G, Santos C, Costa M, Ailion M, Sequeiros J . Functional genomics and biochemical characterization of the C. elegans orthologue of the Machado-Joseph disease protein ataxin-3. FASEB J. 2007; 21(4):1126-36. DOI: 10.1096/fj.06-7002com. View

Paulson H, Perez M, Trottier Y, Trojanowski J, Subramony S, Das S . Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron. 1997; 19(2):333-44. DOI: 10.1016/s0896-6273(00)80943-5. View

10.

Chandrasekar V, Dreyer J . microRNAs miR-124, let-7d and miR-181a regulate cocaine-induced plasticity. Mol Cell Neurosci. 2009; 42(4):350-62. DOI: 10.1016/j.mcn.2009.08.009. View

11.

Winborn B, Travis S, Todi S, Scaglione K, Xu P, Williams A . The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J Biol Chem. 2008; 283(39):26436-43. PMC: 2546540. DOI: 10.1074/jbc.M803692200. View

12.

Lewis B, Burge C, Bartel D . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20. DOI: 10.1016/j.cell.2004.12.035. View

13.

Urabe M, Ding C, Kotin R . Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther. 2002; 13(16):1935-43. DOI: 10.1089/10430340260355347. View

14.

Costa M, Paulson H . Toward understanding Machado-Joseph disease. Prog Neurobiol. 2011; 97(2):239-57. PMC: 3306771. DOI: 10.1016/j.pneurobio.2011.11.006. View

15.

McNeill E, Van Vactor D . MicroRNAs shape the neuronal landscape. Neuron. 2012; 75(3):363-79. PMC: 3441179. DOI: 10.1016/j.neuron.2012.07.005. View

16.

Matos C, de Macedo-Ribeiro S, Carvalho A . Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease. Prog Neurobiol. 2011; 95(1):26-48. DOI: 10.1016/j.pneurobio.2011.06.007. View

17.

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

18.

Brown K, Chu C, Rana T . Target accessibility dictates the potency of human RISC. Nat Struct Mol Biol. 2005; 12(5):469-70. DOI: 10.1038/nsmb931. View

19.

Todi S, Scaglione K, Blount J, Basrur V, Conlon K, Pastore A . Activity and cellular functions of the deubiquitinating enzyme and polyglutamine disease protein ataxin-3 are regulated by ubiquitination at lysine 117. J Biol Chem. 2010; 285(50):39303-13. PMC: 2998082. DOI: 10.1074/jbc.M110.181610. View

20.

Yuan B, Latek R, Hossbach M, Tuschl T, Lewitter F . siRNA Selection Server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res. 2004; 32(Web Server issue):W130-4. PMC: 441504. DOI: 10.1093/nar/gkh366. View